» Articles » PMID: 21561312

Hematopoietic Stem/progenitor Cells Express Functional Mitochondrial Energy-dependent Cystic Fibrosis Transmembrane Conductance Regulator

Abstract

Bone marrow-derived hematopoietic stem/progenitor cells (HSPCs) encompass a wide array of cell subsets with different capacities of engraftment and injured tissue-regenerating potential. The characterization/isolation of the stem cell subpopulations represents a major challenge to improve the efficacy of transplantation protocols used in regenerative medicine. Cystic fibrosis (CF) is one of the diseases whose hope of cure relies on the successful application of cell-based gene therapy. This study was aimed at characterizing murine HSPCs on the basis of their bioenergetic competence and CF transmembrane conductance regulator (CFTR) expression. Positively immunoselected Sca-1(+) HSPCs encompassed 2 populations distinguished by their different size, Sca-1 expression and mitochondrial content. The smaller were the cells, the higher was Sca-1 expression and the lower was the intracellular density of functional mitochondria. Reverse transcription-polymerase chain reaction and western blotting revealed that HSPCs expressed CFTR mRNA and protein, which was also functional, as assessed by spectrofluorimetric and patch-clamp techniques. Inhibition of mitochondrial oxidative phosphorylation by oligomycin resulted in a 70% decrease of both the intracelluar adenosine triphosphate content and CFTR-mediated channel activity. Finally, HSPCs with lower Sca-1 expression and higher mitochondrial content displayed higher CFTR levels. Our findings identify 2 subpopulations in HSPCs and unveil a so-far unappreciated relationship between bioenergetic metabolism and CFTR in HSPC biology.

Citing Articles

High CFTR expression in Philadelphia chromosome-positive acute leukemia protects and maintains continuous activation of BCR-ABL and related signaling pathways in combination with PP2A.

Yang X, Yan T, Gong Y, Liu X, Sun H, Xu W Oncotarget. 2017; 8(15):24437-24448.

PMID: 28445932 PMC: 5421860. DOI: 10.18632/oncotarget.15510.


Hematopoietic and mesenchymal stem cells for the treatment of chronic respiratory diseases: role of plasticity and heterogeneity.

Conese M, Piro D, Carbone A, Castellani S, Di Gioia S ScientificWorldJournal. 2014; 2014:859817.

PMID: 24563632 PMC: 3916026. DOI: 10.1155/2014/859817.


To breathe or not to breathe: the haematopoietic stem/progenitor cells dilemma.

Piccoli C, Agriesti F, Scrima R, Falzetti F, Di Ianni M, Capitanio N Br J Pharmacol. 2013; 169(8):1652-71.

PMID: 23714011 PMC: 3753828. DOI: 10.1111/bph.12253.


Amniotic mesenchymal stem cells: a new source for hepatocyte-like cells and induction of CFTR expression by coculture with cystic fibrosis airway epithelial cells.

Paracchini V, Carbone A, Colombo F, Castellani S, Mazzucchelli S, Di Gioia S J Biomed Biotechnol. 2012; 2012:575471.

PMID: 22315512 PMC: 3270433. DOI: 10.1155/2012/575471.

References
1.
Unwin R, Smith D, Blinco D, Wilson C, Miller C, Evans C . Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood. 2006; 107(12):4687-94. DOI: 10.1182/blood-2005-12-4995. View

2.
Hanrahan J, Wioland M . Revisiting cystic fibrosis transmembrane conductance regulator structure and function. Proc Am Thorac Soc. 2005; 1(1):17-21. DOI: 10.1513/pats.2306009. View

3.
Zink D, Amaral M, Englmann A, Lang S, Clarke L, Rudolph C . Transcription-dependent spatial arrangements of CFTR and adjacent genes in human cell nuclei. J Cell Biol. 2004; 166(6):815-25. PMC: 2172106. DOI: 10.1083/jcb.200404107. View

4.
Grove J, Lutzko C, Priller J, Henegariu O, Theise N, Kohn D . Marrow-derived cells as vehicles for delivery of gene therapy to pulmonary epithelium. Am J Respir Cell Mol Biol. 2002; 27(6):645-51. DOI: 10.1165/rcmb.2002-0056RC. View

5.
Ma T, Thiagarajah J, Yang H, Sonawane N, Folli C, Galietta L . Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest. 2002; 110(11):1651-8. PMC: 151633. DOI: 10.1172/JCI16112. View